Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions. Its news flow centers on the progress of its lead investigational product, laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors.
On this page, readers can follow LGVN news related to key clinical programs in hypoplastic left heart syndrome (HLHS), mild Alzheimer’s disease, pediatric dilated cardiomyopathy (DCM), and aging-related frailty. Company announcements highlight milestones such as pivotal Phase 2b trial enrollment in HLHS (ELPIS II), Phase 2a data in Alzheimer’s disease from the CLEAR MIND study, and regulatory interactions including FDA designations like Orphan Drug, Fast Track, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT).
Longeveron’s news also covers intellectual property developments, including U.S. and Canadian patents for the use of its proprietary mesenchymal stem cells in aging-related frailty, non-ischemic dilated cardiomyopathy, and female sexual dysfunction. Scientific and medical conference activity, such as poster presentations at the Clinical Trials on Alzheimer’s Disease (CTAD) conference and participation in cardiovascular clinical trial forums, provides additional insight into how the company positions laromestrocel within neurodegenerative and cardiovascular research.
Investors and observers can use this LGVN news feed to track clinical trial updates, patent grants, financing transactions disclosed in press releases, and other corporate developments that Longeveron reports through GlobeNewswire and SEC-related communications.
Longeveron Inc. (NASDAQ: LGVN) reported its Q2 2021 financial results, revealing a revenue decline to $0.5 million from $0.9 million year-over-year, primarily due to reduced grant revenue. The company achieved statistically significant results in its Phase 2b Aging Frailty trial for Lomecel-B, but did not meet primary efficacy endpoints at Day 180 compared to placebo. R&D expenses rose 205% to $2.0 million, contributing to a net loss of $5.0 million. However, cash reserves increased significantly to $16.8 million, providing runway through Q4 2022. A conference call is scheduled for today at 8:00 AM EDT.
Longeveron Inc. (NASDAQ: LGVN) announced it will release its second quarter 2021 financial results on August 13, 2021, before US market opening. Management will host a conference call at 8:00 AM to discuss these results. The call can be accessed via multiple phone lines and will be available for replay until August 19, 2021. Longeveron is focused on developing cellular therapies for chronic and life-threatening aging-related conditions, with its lead product, LOMECEL-B™, currently in Phase 1 and 2 clinical trials targeting several serious medical issues.
Longeveron Inc. (NASDAQ: LGVN) has announced the enrollment of the first patient in a Phase 2b clinical trial for Lomecel-B, aimed at infants with Hypoplastic Left Heart Syndrome (HLHS). Funded by the National Heart, Lung, and Blood Institute, this double-blind study will assess the safety and efficacy of the investigational MSC product. With a target enrollment of 38 infants across seven U.S. children's hospitals, the trial builds upon the successful Phase 1 results, which reported no major adverse events. The study aims to improve heart function post-surgery in HLHS patients.
Longeveron Inc. (NASDAQ: LGVN) announced that two abstracts for its investigational cell therapy, Lomecel-B, have been accepted for presentation at the Gerontological Society of America (GSA) 2021 Annual Scientific Meeting, scheduled for November 10-14, 2021, in Phoenix, AZ. The abstracts include:
- A Phase 2b Clinical Trial Assessing Lomecel-B Infusion in Individuals with Aging Frailty
- A Phase 1 Trial Assessing Lomecel-B Infusion in Individuals with Alzheimer’s Disease
This indicates ongoing progress in clinical trials aimed at addressing aging-related conditions.
Longeveron Inc. (NASDAQ: LGVN) announced the acceptance of an abstract for a poster presentation at the 2021 Annual Alzheimer's Association International Conference. This presentation highlights the results of their Phase 1 trial on Lomecel-B infusion in patients with mild Alzheimer’s disease. The trial met its primary endpoint of safety and feasibility, showing no Alzheimer’s Related Imaging Abnormalities (ARIA). Additionally, low-dose Lomecel-B demonstrated a reduction in cognitive decline compared to placebo, measured by the Mini Mental State Exam (MMSE). A Phase 2 trial is anticipated in the second half of 2021.
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology firm, announced that CEO Geoff Green will present virtually at the World Stem Cell Summit on June 17, 2021, at 9:45 AM EDT. The 20-minute presentation will cover a corporate overview and research updates, followed by a 20-minute Q&A session. Interested participants can register for the event via the World Stem Cell Summit and the Investor Forum. Longeveron focuses on developing cellular therapies for aging-related and life-threatening conditions, with its lead product Lomecel-B currently in clinical trials for multiple indications.
Longeveron Inc. (NASDAQ: LGVN) announced that its Co-founder and Chairman, Dr. Joshua M. Hare, will be a panelist at the National Academy of Medicine’s workshop on June 15, 2021. The symposium, titled “Transformative Advances in Biological Sciences for Healthy Longevity,” aims to develop a Global Roadmap for Healthy Longevity. Longeveron is focused on cell-based therapies for aging-related diseases, with ongoing clinical trials for its lead product, Lomecel-B, targeting aging frailty and Alzheimer’s disease. Top-line data from recent trials is expected in Q3 2021.
Longeveron (NASDAQ: LGVN) announced the appointment of Ursula Ungaro to its Board of Directors, effective June 1, 2021. Ungaro, who has served on the U.S. District Court for the Southern District of Florida since 1992, brings extensive legal experience, particularly in civil and securities law. Her retirement from the judiciary was motivated by her desire to contribute to Longeveron's growth in cellular therapies, including the development of Lomecel-B for aging-related conditions. CEO Geoff Green expressed confidence in her ability to guide the company's clinical advancements and commercialization efforts.
Longeveron Inc. (NASDAQ: LGVN) has appointed Dan Gincel, Ph.D., as Senior Vice President of Strategic Collaborations & Scientific Affairs. Gincel brings over 20 years of experience in regenerative medicine, including leadership roles in public-private partnerships. Previously, he managed over $150 million in funding while at the Maryland Stem Cell Research Fund. CEO Geoff Green noted Gincel's expertise will help advance Longeveron's mission to develop cell therapies for aging-related diseases. The company is currently conducting Phase 1 and 2 clinical trials for multiple conditions.
Longeveron Inc. (NASDAQ: LGVN) provided a business update and Q1 financial results as of March 31, 2021. The company is developing allogeneic cell therapies targeting chronic aging-related diseases, including Alzheimer's. Notably, the Phase 1 Alzheimer’s study showed Lomecel-B to be well tolerated with no serious adverse events and evidence of slowing cognitive decline. Longeveron plans to initiate a Phase 2 study in the second half of the year and expects to announce top-line results from Phase 2 Aging Frailty trials in Q3. The upcoming presentations at significant conferences highlight the company's ongoing research.